This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Over 80% of crs with nasal polyps’ patients have type 2 inflammation dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.
MAT-BH-2300364/V1/JUNE 2023
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.